Terafence announced that it has entered into letter of intent to receive $2 million in equity funding from new investor CRI Middleware Co., Ltd. (TSE:3698) on March 15, 2018. Pursuant to the transaction, the investor shall hold 16% stake in the company. The company will sign agreement with investor in late March.